A phase I study of sequential vaccinations with recombinant Fowlpox-PSA (L155)-TRICOM (rF)alone, or in combination with recombinant vaccinia-PSA (L155)-TRICOM (rV), and the role of GM-CSF, in patients (Pts) with prostate cancer

Philip M. Arlen(Dana-Farber Cancer Institute), Jeffrey Schlom(National Cancer Institute), Dennis Panicali(Fox Chase Cancer Center), William Dahut, James L. Gulley(National Cancer Institute), Mary Pazdur(National Institutes of Health), Steven Morin(National Institutes of Health), Lisa Skarupa(National Institutes of Health), N R Todd, K. Y. Tsang
Journal of Clinical Oncology
July 15, 2004
Cited by 10


Related Papers